Lizely Finance Earnings Analysis — Veru Inc. (VERU) Interim Filing: Losses Persist With Mixed Year-over-Year Direction

Bottom line

For the three-month reporting period, Veru Inc. reported a net loss attributable to parent of -$6,988,350 USD, against a prior-year quarter loss of -$7,332,820 USD — a narrower year-over-year loss, classified in the authorized direction as an increase from one loss to a smaller loss. Operating income for the same quarter was a loss of -$7,713,681 USD, compared with a prior-year quarter operating loss of -$7,546,476 USD — an authorized direction decrease, meaning the operating loss widened quarter over quarter. The filing evidence does not attribute this change to any single cause.

For the nine-month year-to-date period, net loss attributable to parent was -$15,062,061 USD, versus a prior-year nine-month loss of -$24,179,786 USD — also an authorized increase from one loss to a smaller loss. Operating income for the nine-month period was a loss of -$20,356,664 USD, compared with a prior-year nine-month operating loss of -$25,917,435 USD, and the authorized direction for that comparison is an increase, meaning the operating loss narrowed over the nine-month window. The filing evidence does not attribute this change to any single cause.

The reporting entity is Veru Inc., filing as VERU INC. under ticker VERU and CIK 0000863894 via form 10-Q for fiscal period period-ended-2026-06-30, accession 0001437749-26-026664. The filing covers two reported windows: the three-month period the three months ended June 30, 2026 versus the prior-year comparable the three months ended June 30, 2025, and the nine-month year-to-date window the nine months ended June 30, 2026 versus the prior-year comparable the nine months ended June 30, 2025. Period-level angles (such as monthly cadence within the quarter) and segment-level breakdowns are not separately disclosed in the evidence catalog for this dimension. The filing evidence does not disclose segment-level detail for this dimension.

Management context wraps the headline numbers: the filing is framed through forward-looking statements about pipeline assets, including enobosarm as a potential adjunct to incretin-based obesity therapy and sabizabulin for cardiovascular atherosclerotic disease, and the filing explicitly references the going-concern note Note 2, reaffirming that the company is not profitable and has had negative cash flow from operations. The going-concern flag is part of the company-disclosed posture accompanying the reported losses in both windows. Net-revenue concentration in the three- and nine-month windows is disclosed in Note 15, and the share-count basis reflects the reverse stock split referenced in Note 9. No peer or industry comparison is contained in the filing evidence. The filing evidence contains no peer or industry comparison.

Counter-evidence and unknowns: the operating-line quarter-over-quarter direction (decrease) moves opposite to the net-loss line (increase, i.e., smaller loss), which is a tension readers should note; the catalog does not authorize a causal bridge between the two, so the discrepancy is left standing without explanation. The legal proceedings, risk factors, and controls-and-procedures items (Item 1, Item 1A, Item 3, Item 4, Item 6) and the equity-related notes Note 1, Note 3, and Note 12 provide supporting context but do not, in the filing evidence, supply per-line attribution of the quarterly operating-loss widening. The takeaway is that profitability has not been reached in either window, the nine-month bottom line improved year-over-year, and the quarterly operating loss moved in the opposite direction — with causation unattributed.

Financial performance

- Reported figures - For the three-month reporting period, Net Income (Loss) Attributable to Parent was -$6,988,350 USD, compared with -$7,332,820 USD in the prior-year comparative three-month period. Both windows remained a loss. - For the nine-month year-to-date period, Net Income (Loss) Attributable to Parent was -$15,062,061 USD, against -$24,179,786 USD in the prior-year comparative nine-month window.

Both windows remained a loss. - For the three-month reporting period, Operating Income (Loss) was -$7,713,681 USD, versus -$7,546,476 USD in the prior-year comparative quarter. Both windows were losses.

- For the nine-month year-to-date period, Operating Income (Loss) was -$20,356,664 USD, against -$25,917,435 USD in the prior-year comparative nine-month window. Both windows were losses. - Year-over-year framing - Net Income (Loss) Attributable to Parent moved higher on both windows year over year, with the three-month comparative quarter and the nine-month comparative year-to-date period each remaining in loss territory.

- Operating Income (Loss) was higher year over year on the nine-month window, while on the three-month window it was lower year over year; both windows remained losses. - Quarter-over-quarter framing - The filing presents the three-month period against its prior-year quarter rather than against a sequential quarter, so a quarter-over-quarter movement for the most recent reporting period is not disclosed within the filing evidence. S.

shutdown. It does not provide quantified revenue, earnings, or operating-income guidance for the next reporting window, and no management metric or range is supplied within the filing evidence. - Accounting context - The cited note on going concern is the principal accounting-context flag carried forward by management; no restatement, change in estimate, or accounting-policy revision is disclosed in the filing evidence for the dimensions above.

- Counter-evidence and unknowns - The filing evidence contains no segment-level breakdown for either net income or operating income on these windows. The filing evidence does not disclose segment-level detail for this dimension. - The filing evidence contains no peer or industry comparison.

The filing evidence contains no peer or industry comparison. - The filing evidence does not attribute the year-over-year movements to any single cause. The filing evidence does not attribute this change to any single cause.

Operating drivers and segments

Operating loss was reported for the three-month reporting period -$7,713,681, wider than the loss recorded in the prior-year comparative -$7,546,476. For the nine-month year-to-date window, the operating result was a loss of -$20,356,664, narrower than the prior-year loss of -$25,917,435. Per the cited note, all of the company's net revenues during the three- and nine-month reporting windows were tied to a single product franchise, with the UK subsidiary and related entities identified as the relevant organizational layer per the cited note; no other operating segment is disclosed. Because the filing does not segment cost of sales, research and development, or selling, general and administrative expense across distinct businesses, segment-level margins cannot be computed from the filing evidence.

Management frames the forward-looking outlook around two drug candidates — enobosarm, pursued in combination with a glucagon-like receptor agonist for obesity-related muscle preservation, and sabizabulin, studied for atherosclerotic cardiovascular disease risk reduction. The cautionary statement enumerates risks spanning clinical-trial recruitment and timing, regulatory alignment with the FDA and foreign authorities, manufacturing-lot release timing, the possibility that early or single-trial results will not replicate in later studies or in clinical practice, and the broader going-concern backdrop referenced in the cited note on the company's ability to continue as a going concern. Management also flags the recent FASB pronouncements on income-tax disclosures and on expense disaggregation under the cited income-statement subtopic as not-yet-adopted items that will eventually reshape the level of detail available in the face of the statement of operations.

Independent analysis: The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison. Independent readers of the operating-loss trajectory can note only that both windows remain loss-making, that the year-to-date loss narrowed relative to the prior-year period, and that the quarterly loss widened year over year; nothing in the cited notes allocates the year-to-date improvement or the quarterly deterioration between higher net revenues, lower research and development spend, lower selling expense, or any other line. The single-product concentration disclosed in the cited revenue note, combined with the going-concern language in the cited note, frames the operating-loss result as the dominant earnings driver for the period. Readers who want to stress-test any implied return assumptions on the company's pipeline spend may find a starting point in ROI Calculator, though no return figure can be inferred from the filing evidence itself.

Cash flow and capital

The nine-month year-to-date window for VERU INC. (VERU, 10-Q for period-ended-2026-06-30, accession 0001437749-26-026664) shows the late-stage biopharmaceutical pattern of operating cash burn partially offset by external financing. Net Cash Provided by (Used in) Operating Activities was -$20,551,655 USD for the nine months ended June 30, 2026, compared with -$24,551,752 USD for the nine months ended June 30, 2025. The authorized comparison reads this as an increase, meaning a smaller cash outflow from operations than in the prior-year period, though the period remained a use of cash rather than a source. The company notes in Note 2 that the Company is not profitable and has had negative cash flow from operations, a statement that remains consistent with the headline operating line.

Net Cash Provided by (Used in) Investing Activities was $5,322,804 USD for the nine months ended June 30, 2026, versus $18,867,232 USD for the nine months ended June 30, 2025. The authorized comparison frames this as a decrease, with both periods still on the positive side of the line. Inside investing, Payments to Acquire Property, Plant, and Equipment was $0 USD for the nine months ended June 30, 2026, against $1,083 USD for the nine months ended June 30, 2025. The authorized comparison frames capex as a decrease to a figure reported at direction zero — effectively no reported capital spending in the current window, consistent with a development-stage issuer that is not building commercial-scale manufacturing.

Net Cash Provided by (Used in) Financing Activities was $23,314,431 USD for the nine months ended June 30, 2026, compared with -$4,221,611 USD for the nine months ended June 30, 2025. The authorized comparison reads this as an increase, moving from a use of cash in the prior year to a source of cash in the current window — the external funding side of the picture. The filing evidence does not attribute this change to any single cause.

On the balance sheet side, period-end liquidity is reflected in Cash and Cash Equivalents, at Carrying Value of $23,880,142 USD at the balance sheet date of June 30, 2026. Working-capital obligations appear in Accounts Payable and Other Accrued Liabilities, Current of $949,092 USD and Accounts Payable, Current of $1,709,689 USD, both at the balance sheet date of June 30, 2026.

Capital allocation is weighted toward the clinical pipeline rather than fixed assets: minimal capex, continuing operating burn, and financing inflows plugging the gap. The prior-year financing figure being negative and the current financing figure being positive indicates that external capital was raised in the current nine-month window to fund loss-making operations. The filing evidence does not attribute this change to any single cause. The filing evidence contains no peer or industry comparison.

Peer and historical context

- Against the prior-year nine-month window, operating-cash outflows narrowed for VERU INC. per 10-Q period-ended-2026-06-30 under accession 0001437749-26-026664, indicating reduced cash burn from operations across the nine months ended June 30, 2026 relative to the nine months ended June 30, 2025; the cited note Note 2 still frames the Company as unprofitable with negative operating cash flow, so the year-over-year tightening is a relative improvement, not a return to positive cash generation. - Operating losses also contracted on the year-to-date comparison: the nine-month operating loss for the nine months ended June 30, 2026 was smaller than the loss recorded for the nine months ended June 30, 2025, consistent with the same direction of change seen on the cash-flow line and suggesting that the operating-side improvement was broad enough to show up in both accrual operating income and operating cash.

- The quarterly picture is more mixed. The three-month operating loss for the three months ended June 30, 2026 widened compared with the three months ended June 30, 2025, moving in the opposite direction from the year-to-date operating loss and from the operating-cash comparison, so the year-to-date improvement is not being maintained at a uniform pace into the most recent quarter. - Net loss attributable to parent likewise narrowed year-to-date — the nine-month net loss for the nine months ended June 30, 2026 was smaller than the loss for the nine months ended June 30, 2025 — and the three-month net loss for the three months ended June 30, 2026 was smaller than the loss for the three months ended June 30, 2025, so the bottom-line trend on a quarter-over-quarter basis aligns with the year-to-date narrowing even though the operating-loss comparison diverges between those two windows.

- Capital spending has effectively stopped: payments to acquire property, plant, and equipment fell to zero for the nine months ended June 30, 2026 from a positive level in the nine months ended June 30, 2025, reinforcing the narrative of a development-stage company conserving cash while it works through its drug pipeline rather than expanding fixed-asset capacity. - The Company exited its commercial product line, since the cited note Note 15 states that all net revenues during both the three- and nine-month periods ending in the reported quarter came from sales that are now included within discontinued operations, which means the historical revenue comparison itself is not like-for-like and any apparent top-line change overstates the shift in continuing operations.

- The filing evidence contains no peer or industry comparison. - The filing evidence does not attribute this change to any single cause. - Investing-activity cash flow moved from a positive amount in the nine months ended June 30, 2025 to a smaller positive amount in the nine months ended June 30, 2026, while financing-activity cash flow flipped from a use of cash in the prior-year nine-month period to a source of cash in the nine months ended June 30, 2026, pointing to a financing-led funding model for a development-stage issuer that is no longer generating material revenue from continuing operations and that, per the going-concern note Note 2, needs substantial additional capital to fund its drug-development program.

- For readers comparing peer or industry benchmarks on return profiles, an ROI Calculator is one way to translate any per-share loss reading into a comparable return context.

Scenario analysis

- In a continuation case, VERU INC. (VERU, filing 10-Q for period-ended-2026-06-30, accession 0001437749-26-026664) carries forward the same profitability profile already embedded in this interim period: a net loss attributable to parent in both reporting windows. - The ledger shows -$24,179,786 for the prior-year nine-month comparative and -$7,332,820 for the prior-year three-month comparative, against -$15,062,061 for the nine months ended June 30, 2026 and -$6,988,350 for the three months ended June 30, 2026 — a continuation of the loss position. - On a reported year-over-year basis, the net loss attributable to parent was higher in the nine months ended June 30, 2026 than in the nine months ended June 30, 2025 (a loss-to-loss transition), and similarly higher in the three months ended June 30, 2026 than in the three months ended June 30, 2025 (also a loss-to-loss transition). - The going-concern note (Note 2) is the binding constraint: management states that the Company's cash and cash equivalents as of the issuance date are insufficient for the operating, investing and financing cash flow needs for the twelve months subsequent to issuance, and that substantial doubt exists about the ability to continue as a going concern for that period. A continuation case therefore assumes that the planned equity, debt and/or other capital sources materialize on terms sufficient to fund operations across the next twelve months.

- An upside case hinges on the outside-of-management-control capital actions described in Note 2 actually closing on terms that more than fund the twelve-month operating plan, removing the going-concern qualification and allowing development and commercialization spend to accelerate. - Discontinued-operations context in Note 3 — the prior-period Business Sale to Clear Future, Inc. of the assets related to the cited business — has already narrowed the operating footprint, which simplifies the perimeter against which any capital raise would have to be measured. - In this case, the reporting losses in the nine months ended June 30, 2026 and the three months ended June 30, 2026 (-$15,062,061 and -$6,988,350) would be the starting point against which management could demonstrate that incremental financing translated into forward-progress metrics rather than just a wider loss. - The filing evidence contains no peer or industry comparison. - Readers weighing the required-investment math against expected returns can frame that judgment with ROI Calculator.

- The downside is the going-concern scenario from Note 2 playing out: management states that certain elements of the operating plan to alleviate the conditions that raise substantial doubt are outside of its control and cannot be included in management's evaluation under the cited ASC guidance, and that substantial doubt therefore exists about the ability to continue as a going concern for at least twelve months subsequent to the issuance date. - In that path, the loss-to-loss profile of -$15,062,061 versus -$24,179,786 (reported: higher loss this period) and -$6,988,350 versus -$7,332,820 (reported: higher loss this period) compounds against an inability to fund drug-development and commercialization efforts for the Company's drug candidates. - Additional pressure would come from the still-to-be-adopted ASU wave referenced in the accounting-pronouncements discussion, including the disaggregation and interim-reporting improvements; the Company itself states it is currently evaluating the impact of adopting those standards on its consolidated financial statements and disclosures. - The filing evidence does not attribute this change to any single cause. - The unresolved unknowns are the timing, size and counterparties of any financing transaction — none of which the filing evidence specifies.

Risks and what to watch

- Reported facts: The filing's net-income line is negative on every window surfaced by this section. The three-month reporting period produced a net loss attributable to parent of -$6,988,350 USD against a prior-year three-month net loss of -$7,332,820 USD for the three months ended June 30, 2025. The nine-month year-to-date period produced a net loss attributable to parent of -$15,062,061 USD against a prior-year nine-month net loss of -$24,179,786 USD for the nine months ended June 30, 2025.

Both windows therefore remain in loss territory, and the year-over-year change in net loss is an authorized increase on both the quarter and the nine-month comparison. - Management explanations: The cited note titled Going Concern states that the Company "is not profitable and has had negative cash flow from operations," that "substantial capital" is needed to support drug development and related commercialization, and that cash and cash equivalents at the issuance date are insufficient to fund operating, investing, and financing cash-flow needs for twelve months subsequent to issuance.

Management expects to fund cash needs through public or private equity offerings, debt financing transactions, and other capital sources, and concludes that substantial doubt exists about the ability to continue as a going concern for at least twelve months. - Counter-evidence: Operating cash flow on the nine-month window narrowed on the authorized direction (an increase from a larger outflow to a smaller outflow), financing-activities cash flow shifted directionally (from a use to a source), and investing-activities cash flow decreased on the authorized direction while remaining positive — these are the only authorized directional statements about cash flows and they do not, on their own, refute the going-concern qualification.

, a structural change that the filing narrates but does not connect explicitly to any single net-loss driver. The filing evidence does not attribute this change to any single cause. - Analyst inference: Because the going-concern paragraph fixes the horizon at twelve months from issuance and the cited note on Stockholders' Equity describes a reverse stock split effected under the cited reference, equity-raising capacity, post-split share count, and post-sale cash burn are the variables an outside reader can actually monitor next period; peer benchmarking against other development-stage pharmaceutical issuers is not feasible here because The filing evidence contains no peer or industry comparison.

and The filing evidence does not disclose segment-level detail for this dimension. both apply. The cited Quantitative and Qualitative Disclosures About Market Risk item and the Risk Factors section under the cited forward-looking-statements legend are the filing's own channels for surfacing new risks between now and the next interim.

- Unknowns: The filing does not attribute the year-over-year change in net loss on either window to a single cause, so any narrative on operating drivers must defer to The filing evidence does not attribute this change to any single cause.. The exact closing cash balance at the issuance date, the size of any prospective financing, the post-split share count, and any milestone payments tied to the sold business are not given in numeric form within this section's catalog and therefore cannot be quantified here. - Metrics to watch next period: net loss attributable to parent for the next reporting window, cash and cash equivalents at period end relative to the twelve-month funding need flagged in the cited note, any equity or other capital raise disclosed under the cited Stockholders' Equity note, and any update to the risk-factor language carried under the cited Reference items.

Readers modeling capital needs for a development-stage issuer can pair this filing with the ROI Calculator when sizing a hypothetical financing outcome, though that is purely a framing exercise and not a forecast by this analysis.